Fexuprazan (Fexuclue®): A Comprehensive Monograph on a Novel Potassium-Competitive Acid Blocker

The Evolving Landscape of Acid Suppression and the Advent of Fexuprazan

The Global Burden of Acid-Related Disorders (ARDs)

Acid-related disorders (ARDs), a group of conditions primarily caused by the excessive or imbalanced production of gastric acid, represent a significant and growing global health burden.[1] Conditions such as gastroesophageal reflux disease (GERD), peptic ulcer disease, and gastritis are among the most common diagnoses made in clinical practice worldwide. The prevalence of GERD, in particular, has been steadily increasing in both Asian and Western nations, with a recent estimate placing its worldwide prevalence at 13.3%.[2] This high incidence underscores the vast and persistent clinical need for effective, reliable, and convenient acid-suppressive therapies.

The Era of Proton Pump Inhibitors (PPIs): The Gold Standard and Its Limitations

Since their introduction in the late 1980s, proton pump inhibitors (PPIs) have been the cornerstone of ARD management, establishing themselves as the first-line therapeutic gold standard due to their potent acid-suppressing capabilities.[1] However, despite their widespread efficacy, the PPI class possesses several inherent pharmacological and clinical limitations that have created a distinct unmet clinical need.[5] These limitations include:

• Delayed Onset of Action: PPIs are pro-drugs that are unstable in acid and thus require an enteric coating. They must be absorbed in the intestine, enter the systemic circulation, and then reach the parietal cells, where they are activated by the acidic environment of the secretory canaliculus.[2] This multi-step process results in a gradual onset of effect, with maximal efficacy and pharmacodynamic steady-state often not achieved until after 3 to 5 days of continuous daily dosing.[5]
• Food-Drug Interaction: For optimal efficacy, PPIs must be administered prior to a meal. This timing is crucial because PPIs irreversibly bind to and inhibit only actively secreting proton pumps, which are stimulated by food intake.[2] This meal-dependent dosing regimen can be inconvenient for patients and is a common cause of suboptimal adherence and treatment failure.[7]
• Metabolic Variability: Many widely used PPIs are primarily metabolized by the cytochrome P450 2C19 (CYP2C19) enzyme.[1] The gene for this enzyme is highly polymorphic, leading to significant inter-individual variability in drug exposure and clinical response. Patients who are "rapid metabolizers" may experience treatment failure, while "poor metabolizers" may have increased drug levels and a higher risk of adverse effects.[3]
• Suboptimal Nocturnal Acid Control: A significant portion of patients on once-daily PPI therapy experience nocturnal acid breakthrough, a phenomenon where intragastric pH drops below 4 for a sustained period overnight.[6] This is largely due to the relatively short plasma half-life of most PPIs (approximately 1-2 hours) and is a primary driver of patient dissatisfaction, persistent symptoms, and sleep disturbances.[1]

These well-documented shortcomings translate into a considerable rate of patient dissatisfaction, with up to 40% of individuals treated with PPIs for GERD reporting an inadequate response to therapy.[10]

The Emergence of Potassium-Competitive Acid Blockers (P-CABs): A New Paradigm

In response to the clear unmet needs left by PPIs, a new class of acid suppressants, the potassium-competitive acid blockers (P-CABs), was developed.[1] This class was engineered through a process of rational drug design specifically to overcome the inherent limitations of the previous therapeutic standard. Fexuprazan (development code DWP14012), a novel P-CAB developed by Daewoong Pharmaceutical Co., Ltd. of South Korea, has emerged as a significant new entrant in this class, alongside other agents like vonoprazan and tegoprazan.[1] The development of Fexuprazan and the broader P-CAB class signals a pivotal shift in the treatment of ARDs, moving beyond a singular focus on maximal acid suppression to prioritize attributes of predictability, rapid action, and patient convenience.

Pharmacological and Pharmacodynamic Profile

The distinct clinical advantages of Fexuprazan are directly rooted in its unique molecular mechanism and its predictable pharmacokinetic profile. This profile was intentionally designed to address the specific failures of PPIs, resulting in a more reliable and convenient therapeutic agent.

Molecular Mechanism of Action: A Fundamental Shift from PPIs

Fexuprazan shares the same molecular target as PPIs—the gastric H+/K+-ATPase, or proton pump—but inhibits it through a fundamentally different mechanism.[13]

• Reversible, K+-Competitive Inhibition: Unlike PPIs, which form an irreversible covalent disulfide bond with the proton pump, Fexuprazan functions as a potassium-competitive inhibitor. It binds directly and ionically to the K+ binding site of the H+/K+-ATPase, preventing the exchange of H+ for K+ and thereby halting acid secretion.[2] This binding is both competitive and fully reversible.
• Action on Active and Inactive Pumps: Fexuprazan does not require activation by acid. As a result, it can bind to and inhibit proton pumps in both their resting (inactive) and active states.[2] This is a critical distinction from PPIs, which can only bind to active pumps, and it is a primary reason for Fexuprazan's rapid onset of action.
• High Concentration at Target Site: As a weak base, Fexuprazan has a high acid dissociation constant (pKa). This property causes it to accumulate to extremely high concentrations—potentially 100,000-fold higher than in plasma—within the highly acidic secretory canaliculi of the parietal cells, ensuring potent and localized inhibition of the proton pumps.[11]

Pharmacokinetic (ADME) Characteristics: The Foundation of Predictability

The pharmacokinetic profile of Fexuprazan underpins its entire clinical value proposition, with each characteristic directly addressing a known limitation of PPIs.

• Absorption: Fexuprazan is rapidly absorbed following oral administration, reaching maximum plasma concentration (Tmax​) in a median of 1.75 to 3.5 hours.[9] Physiologically based pharmacokinetic (PBPK) modeling has estimated a high fraction absorbed ( Fa​) of 0.761, with a final oral bioavailability of approximately 38.4% to 38.6%.[16] A pivotal feature is its acid stability, which obviates the need for an enteric coating and allows its pharmacokinetic and pharmacodynamic properties to be independent of food intake, granting flexibility in dosing.[2]
• Distribution: The drug is highly bound to human plasma proteins (92.8% to 94.3%), which tends to confine it to the vascular space until it reaches its target tissues.[15] PBPK models have effectively characterized its distribution across 13 physiological compartments, assuming a perfusion-limited distribution model appropriate for a highly permeable compound.[16]
• Metabolism: Fexuprazan is primarily metabolized in the liver, predominantly by the cytochrome P450 3A4 (CYP3A4) enzyme.[1] Its main metabolite, M14, is considered pharmacologically inactive.[15] Crucially, its metabolism is largely independent of the polymorphic CYP2C19 pathway, which is a major source of inter-patient variability for many PPIs. This metabolic pathway results in a predictable dose-response relationship with minimal variability between individuals.[1]
• Excretion: Elimination occurs primarily through hepatic metabolism. Renal excretion of the unchanged drug is minimal, accounting for only about 0.6% of an administered dose.[15] Fexuprazan is characterized by a long mean elimination half-life ( t1/2​) of approximately 9 to 9.7 hours, which is substantially longer than that of traditional PPIs.[6]

Pharmacodynamics and Novel Mechanisms: Beyond Acid Suppression

The combination of Fexuprazan's mechanism and pharmacokinetics translates into a superior pharmacodynamic profile. The rapid absorption and ability to inhibit inactive pumps lead to a swift onset of acid suppression, with studies showing gastric pH rising above 4 within two hours of the first dose.[2] The long elimination half-life ensures that this profound acid suppression is maintained over a full 24-hour period, effectively addressing the issue of nocturnal acid breakthrough common with PPIs.

Furthermore, recent pre-clinical research has uncovered a novel mechanism that may differentiate Fexuprazan from other acid suppressants. In a study using human esophageal cells, Fexuprazan was shown to significantly attenuate hydrochloric acid-induced pyroptosis, a highly inflammatory form of programmed cell death. It achieved this by suppressing the NLRP1/Caspase-1/GSDMD pyroptotic pathway and reducing the release of the pro-inflammatory cytokine IL-1β.[13] This finding suggests that Fexuprazan may possess a dual action: not only reducing the acidic insult to the esophagus but also actively protecting the esophageal mucosa from inflammation and damage. If validated in clinical settings, this mucosal-protective effect could represent a significant therapeutic advantage.

Table 1: Comparative Pharmacological Profile: Fexuprazan vs. Traditional PPIs
Parameter	Fexuprazan (P-CAB)	Typical PPIs
Mechanism of Action	Reversible, K+-competitive ionic binding	Irreversible, covalent binding
Target State	Active and inactive H+/K+-ATPase	Active H+/K+-ATPase only
Activation Requirement	None (direct action)	Requires activation by acid
Onset of Action	Rapid (within hours)	Delayed (3-5 days for full effect)
Elimination Half-Life	Long (~9 hours)	Short (~1-2 hours)
Effect of Food	None; can be taken with or without food	Efficacy is meal-dependent
Primary Metabolism	CYP3A4 (low polymorphism)	CYP2C19 (high polymorphism)
Nocturnal Acid Control	Sustained 24-hour control	Prone to nocturnal acid breakthrough

Table 2: Summary of Fexuprazan Pharmacokinetic Parameters
Parameter	Value
Time to Max. Concentration (Tmax​)	1.75–3.5 hours
Oral Bioavailability	~38.5%
Plasma Protein Binding	92.8%–94.3%
Elimination Half-Life (t1/2​)	~9–9.7 hours
Primary Metabolic Pathway	Hepatic (CYP3A4)
Renal Excretion (unchanged)	~0.6%

Analysis of Clinical Efficacy from Phase III and IV Trials

The clinical development program for Fexuprazan has been strategically designed to establish its role in the modern treatment of ARDs. This strategy involved demonstrating parity with the gold standard in the competitive erosive esophagitis market while simultaneously proving superiority in the underserved gastritis market to secure a unique indication.

Erosive Esophagitis (EE): Establishing Non-Inferiority to the Gold Standard

Multiple large-scale, Phase III, randomized, double-blind, multicenter studies were conducted to compare the efficacy and safety of Fexuprazan 40 mg once daily against the standard-of-care, esomeprazole 40 mg once daily, in patients with endoscopically confirmed EE.[2]

The primary endpoint in these trials was the rate of endoscopically confirmed mucosal healing at week 8. Across these studies, Fexuprazan consistently and robustly demonstrated non-inferiority to esomeprazole. In a pivotal trial involving 332 subjects, the 8-week healing rate in the per-protocol set (PPS) was 97.3% for Fexuprazan versus 97.9% for esomeprazole.[22] A separate Korean study reported similarly high rates of 99.1% for both treatment arms.[2] These results successfully met the primary objective required for regulatory approval, establishing Fexuprazan as an equally effective agent for healing esophageal erosions.

Secondary endpoints provided further nuance. Healing rates at week 4 were also comparable between the groups, with some studies showing a numerical trend favoring Fexuprazan (e.g., 84.6% vs. 80.8%), although this difference was not statistically significant.[23] While overall symptom response and improvements in quality of life scores were similar, a key finding emerged from data presented at Digestive Disease Week (DDW) 2020. In the sub-group of patients with moderate-to-severe symptoms, Fexuprazan demonstrated significantly faster and more effective relief of heartburn compared to esomeprazole, an effect that was sustained through the night.[25] For patients suffering from severe, disruptive symptoms, this rapid relief is a clinically meaningful advantage.

Table 3: Pivotal Phase III Trial Results in Erosive Esophagitis: Fexuprazan vs. Esomeprazole
Endpoint	Fexuprazan 40 mg	Esomeprazole 40 mg
EE Healing Rate at Week 8 (PPS)	97.3% (145/149)	97.9% (143/146)
EE Healing Rate at Week 4 (PPS)	84.6% (126/149)	80.8% (118/146)
Drug-Related Adverse Events	19.4% (32/165)	19.6% (32/163)
Data synthesized from a multicenter, randomized, double-blind study in China.22

Acute and Chronic Gastritis: Carving a Unique Indication

A cornerstone of Fexuprazan's clinical strategy was to establish its efficacy in gastritis, a common condition that has historically lacked a formally approved, evidence-based therapy.[26] A pivotal Phase III, multicenter, placebo-controlled trial (NCT04341454) evaluated Fexuprazan for the amelioration of gastric mucosal lesions in patients with acute or chronic gastritis.[26]

The primary endpoint was the rate of improvement in gastric erosions after two weeks of treatment. Both Fexuprazan dosing regimens demonstrated statistically significant superiority over placebo. The erosion improvement rate was 65.7% in the Fexuprazan 10 mg twice-daily (b.i.d.) group (p<0.001 vs. placebo) and 57.8% in the Fexuprazan 20 mg once-daily (q.d.) group (p=0.017 vs. placebo), compared to only 40.6% in the placebo group.[26] This clear demonstration of superiority in a well-controlled trial allowed Fexuprazan to become the first P-CAB approved for this indication in South Korea, creating a distinct and valuable market niche.[1]

Investigational and Future Applications: Expanding the Frontier

The clinical investigation of Fexuprazan continues to expand into new therapeutic areas, aiming to leverage its favorable pharmacologic profile.

• Maintenance Therapy for GERD: A prospective study explored patient preferences and outcomes for maintenance therapy after an initial 4-week healing course with Fexuprazan. A significant majority of patients (67.7%) chose an "on-demand" therapy strategy for maintenance, taking the medication only when symptoms occurred. This patient-preferred approach proved to be as effective as continuous daily therapy in controlling symptoms over the subsequent 4 weeks.[21] This finding is potentially transformative, as it validates a less burdensome, more patient-centric long-term management strategy that could improve adherence and reduce healthcare costs.
• GERD-Related Chronic Cough: In a Phase IV exploratory trial, Fexuprazan demonstrated comparable efficacy to esomeprazole in improving cough-related quality of life in patients with chronic cough associated with GERD, supporting its potential use for this common extraesophageal manifestation.[10]
• Gastroprotection: Recognizing the need for effective gastroprotection in high-risk populations, ongoing clinical trials are evaluating Fexuprazan for the prevention of peptic ulcers induced by non-steroidal anti-inflammatory drugs (NSAIDs).[4] Another trial (NCT05946135) is assessing its ability to prevent gastritis symptoms in patients receiving long-term systemic steroid therapy.[29]
• Other Indications: The development pipeline remains active, with Phase III trials also underway for non-erosive reflux disease (NERD) and as part of combination therapy for Helicobacter pylori eradication.[12]

Comprehensive Safety, Tolerability, and Risk Profile

An extensive clinical trial program has established that Fexuprazan possesses a favorable and manageable safety profile, which is a critical factor for its adoption in a market with well-entrenched incumbents.

Adverse Event Profile from Clinical Trials

The overall safety and tolerability of Fexuprazan have been shown to be comparable to that of esomeprazole. In the large Phase III EE trials, the incidence of drug-related adverse events was virtually identical between the groups, occurring in 19.4% of patients receiving Fexuprazan and 19.6% of those receiving esomeprazole.[22] Similarly, safety outcomes were comparable in the gastritis trials.[26]

The most commonly reported adverse events (with an incidence of 1% or more) are generally mild to moderate in severity and are primarily gastrointestinal or neurological. These include indigestion, diarrhea, nausea, abdominal discomfort, and headache.[15] A wide array of other events have been reported in less than 1% of patients, but no consistent or concerning safety signals have emerged from these rare events. Importantly, no unexpected serious adverse reactions attributable to Fexuprazan have been observed in the clinical trial programs to date.[19]

Table 4: Common Treatment-Emergent Adverse Events from a Pivotal Phase III EE Trial
Adverse Event	Fexuprazan 40 mg (n=165)	Esomeprazole 40 mg (n=163)
Indigestion	≥1%	≥1%
Diarrhea	≥1%	≥1%
Nausea	≥1%	≥1%
Abdominal Discomfort	≥1%	≥1%
Headache	≥1%	≥1%
Data derived from product information and clinical trial reports.15 Specific percentages for each event were not consistently reported across all sources but were noted as the most common events with an incidence of 1% or more.

Contraindications and Drug-Drug Interactions

Fexuprazan is contraindicated in patients with a known hypersensitivity to the drug or its components. Due to its potent effect on gastric pH, it is also contraindicated for use with certain antiretroviral drugs (atazanavir, nelfinavir, rilpivirine) whose oral absorption is dependent on an acidic environment.[15] Due to a lack of clinical data, its use is also contraindicated during pregnancy and lactation.[15]

As a substrate of CYP3A4, Fexuprazan has the potential for drug-drug interactions. However, dedicated studies have shown this risk to be low. Co-administration with the strong CYP3A4 inhibitor clarithromycin resulted in only a minor, clinically insignificant increase in Fexuprazan exposure.[15] Furthermore, studies evaluating its use with aspirin and several common NSAIDs (celecoxib, naproxen, meloxicam) found no clinically meaningful pharmacokinetic interactions.[8] This clean interaction profile is a significant advantage, particularly in older patients on polypharmacy who often require both anti-inflammatory/antiplatelet agents and gastroprotection.

Warnings, Precautions, and Potential Class Effects

The product labeling for Fexuprazan includes several warnings and precautions, many of which are common to all potent acid-suppressing agents.

• Masking of Malignancy: A critical warning is that by alleviating symptoms, Fexuprazan may mask the signs of a gastric malignancy and delay its diagnosis. It is imperative to rule out malignancy in the presence of alarm symptoms such as unintended weight loss, recurrent vomiting, or dysphagia.[15]
• Potential Long-Term Class Effects: While long-term safety data specific to Fexuprazan are still being collected, its labeling includes warnings extrapolated from the extensive experience with the PPI class regarding the theoretical risks of long-term, profound acid suppression.[11] These include a potential increased risk of gastrointestinal infections (e.g., Clostridium difficile), osteoporosis-related fractures with high-dose or long-term use, and rare instances of hypomagnesemia. As with all potent acid suppressants, Fexuprazan causes a physiological rise in serum gastrin levels, an effect that warrants long-term surveillance.[2]

By mirroring the well-understood and manageable safety profile of esomeprazole, Fexuprazan effectively de-risks the clinical decision to adopt it, allowing prescribers to focus on its benefits of convenience and predictability.

Global Regulatory and Commercial Trajectory

Fexuprazan's journey from a novel drug developed in South Korea to an emerging global product is characterized by a rapid and ambitious commercialization strategy executed by its originator, Daewoong Pharmaceutical.

Regulatory Pathway and Approval Status

Fexuprazan was developed as a new molecular entity by Daewoong Pharmaceutical.[6] It received its first regulatory approval in 2021 from South Korea's Ministry of Food and Drug Safety (MFDS) for the treatment of erosive esophagitis.[4] This was followed by an additional approval for the improvement of gastric mucosal lesions associated with acute and chronic gastritis.[1]

Following its domestic success, Daewoong embarked on an aggressive global expansion, prioritizing high-growth markets in Asia and Latin America. As of early 2024, Fexuprazan (marketed internationally as Fexuclue®) has secured approvals in the Philippines (November 2022), Ecuador (January 2023), Chile (February 2023), and Mexico.[19] In July 2023, a New Drug Application (NDA) was submitted to China's National Medical Products Administration (NMPA) following the successful completion of local Phase III trials.[34] The company has stated a goal of submitting NDAs in 30 countries by 2025 and ultimately launching in 100 countries by 2027.[32]

Regarding the key North American market, an initial licensing agreement with Neurogastrx for the U.S. and Canada was mutually terminated in June 2023. Daewoong has since regained all development and commercialization rights for these territories and is actively exploring strategic partnerships with larger multinational pharmaceutical companies capable of supporting a broader, multi-indication development program.[37] Fexuprazan currently remains an investigational new drug in the United States.[19]

Market Penetration and Commercial Strategy

Fexuprazan has achieved remarkable commercial success in its home market of South Korea, serving as a powerful proof of concept for its global potential. In 2023, it generated sales of KRW 55 billion (approximately USD 40 million), and within just 17 months of its launch, it ascended to the number two position in the domestic GERD treatment market.[38]

Daewoong's strategy involves leveraging strategic partnerships to maximize market penetration. In South Korea, a co-marketing agreement with Chong Kun Dang aims to achieve combined domestic sales of 300 billion won by 2030.[39] Internationally, licensing deals have been secured with regional leaders, including Sun Pharma for the Indian market and a USD 20.32 million deal with Cooper Pharma for Morocco and other African markets.[40]

The drug's clinical benefits have translated into strong brand recognition and patient acceptance. In Mexico, its convenient, meal-independent dosing has led to high patient satisfaction, earning it the nickname the "Korean Pill" among patients and prescribers.[7] Daewoong has also pursued a sophisticated product line strategy, developing multiple tablet strengths (10 mg, 20 mg, and 40 mg) to target different indications and patient needs, including a size-reduced tablet to improve medication compliance.[1] This rapid accumulation of international approvals and strong sales data has significantly increased the drug's value, positioning Daewoong to secure a top-tier partner for a major launch in the lucrative U.S. and European markets.

Synthesis, Clinical Recommendations, and Future Outlook

Positioning Fexuprazan in the Clinical Armamentarium

Fexuprazan has firmly established itself as a safe and highly effective acid-suppressing agent. For erosive esophagitis, it is a premier alternative to PPIs, offering comparable healing efficacy combined with significant advantages in convenience and predictability. For gastritis, it represents a new, evidence-based standard of care. The clinical conversation should therefore evolve from asking "is it better?" to identifying "for whom is it better?".

Fexuprazan should be considered a first-line therapeutic option for specific patient populations who are most likely to benefit from its unique pharmacological profile:

• Patients with significant nocturnal reflux symptoms: The long half-life and sustained 24-hour acid control directly address a primary shortcoming of PPIs.
• Patients with poor or uncertain adherence: The meal-independent dosing regimen simplifies treatment and removes a common barrier to effective therapy.
• Patients on polypharmacy: The CYP3A4-mediated metabolism provides a more predictable profile and avoids potential interactions with drugs metabolized by CYP2C19 (e.g., clopidogrel).
• Patients with an inadequate symptomatic response to once-daily PPIs: The rapid and potent acid suppression may provide superior symptom control in this group.
• Patients with acute or chronic gastritis: As the first P-CAB with a specific, approved indication based on superiority data, it should be a primary therapeutic choice.

Unresolved Questions and Future Research Imperatives

Despite the robust data package, critical questions remain that will shape the long-term role of Fexuprazan.

• Long-Term Safety: While short-term data are reassuringly benign, prospective, multi-year safety data are essential to confirm that the risks associated with long-term, profound acid suppression are no greater than those observed with PPIs.[11]
• Head-to-Head P-CAB Trials: There is a notable absence of direct, head-to-head comparative trials between Fexuprazan and other P-CABs like vonoprazan. Such studies are needed to delineate potential differences in efficacy, safety, or utility in specific patient subgroups.
• Clinical Validation of Novel Mechanisms: The pre-clinical discovery of an anti-pyroptotic, mucosal-protective effect is intriguing but requires clinical validation.[13] Future studies could incorporate inflammatory biomarkers or histological assessments to determine if this mechanism translates into tangible clinical benefits.
• Efficacy in Special Populations: Data on the use of Fexuprazan in patients with severe renal or hepatic impairment, as well as in pediatric populations, are currently lacking and represent an important area for future investigation.

Future Outlook: The "P-CAB Wars" and Beyond

Fexuprazan is poised to become a major force in the global ARD market, fundamentally challenging the decades-long dominance of PPIs. Its success is driven by a paradigm shift towards valuing patient-centric outcomes—rapid relief, convenience, and predictable efficacy. The next competitive phase will likely be the "P-CAB wars," where Fexuprazan will need to differentiate itself from other drugs in its class. Its unique approved indication for gastritis and its potential mucosal-protective properties could serve as key strategic advantages. The ultimate realization of its blockbuster potential will depend on Daewoong Pharmaceutical's ability to secure a strong, top-tier partner to navigate the complex regulatory and commercial landscapes of the United States and Europe. With its compelling clinical data and proven market success, Fexuprazan is exceptionally well-positioned to make this transition from a Korean success story to a true global therapeutic standard.

Works cited

1. A Comparative Pharmacokinetic Study of Fexuprazan 10 mg: Demonstrating Bioequivalence with the Reference Formulation and Evaluating Steady State, accessed August 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10458111/
2. Randomized controlled trial to evaluate the efficacy and safety of ..., accessed August 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9730436/
3. RETRACTED: A Phase III Head-to-Head Study to Compare the Efficacy and Safety of Fexuprazan and Esomeprazole in Treating Patients with Erosive Esophagitis - MDPI, accessed August 29, 2025, https://www.mdpi.com/2077-0383/13/11/3262
4. Review of the clinical development of fexuprazan for gastroesophageal reflux–related disease - ResearchGate, accessed August 29, 2025, https://www.researchgate.net/publication/371781684_Review_of_the_clinical_development_of_fexuprazan_for_gastroesophageal_reflux-related_disease
5. Observed and simulated time-concentration profiles for fexuprazan at... - ResearchGate, accessed August 29, 2025, https://www.researchgate.net/figure/Observed-and-simulated-time-concentration-profiles-for-fexuprazan-at-the-first-doses-of_fig2_351997815
6. Size-reduced fexuprazan 20 mg demonstrated the optimal bioavailability and bioequivalence with the reference formulation - PMC, accessed August 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10079506/
7. Daewoong's 'Fexuprazan,' the GERD Treatment Chosen by 30 Countries, Accelerates Entry into Indonesia, accessed August 29, 2025, https://daewoong.id/Module/Board/Board.asp?ModuleID=2&Mode=V&IDX=138
8. Pharmacodynamic and Pharmacokinetic Drug Interactions between Fexuprazan, a Novel Potassium-Competitive Inhibitor, and Aspirin, in Healthy Subjects - MDPI, accessed August 29, 2025, https://www.mdpi.com/1999-4923/15/2/549
9. A Comparative Pharmacokinetic Study of Fexuprazan 10 mg ... - MDPI, accessed August 29, 2025, https://www.mdpi.com/1424-8247/16/8/1141
10. Efficacy and Safety of Fexuprazan Versus Esomeprazole for Gastroesophageal Reflux Disease-Related Chronic Cough: A Randomized, Double-Blind, Active-Controlled Exploratory Trial, accessed August 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12041137/
11. Potassium-competitive Acid Blockers: Current Clinical Use and Future Developments - PMC, accessed August 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11401795/
12. Fexuprazan - Daewoong Pharmaceutical - AdisInsight - Springer, accessed August 29, 2025, https://adisinsight.springer.com/drugs/800045288
13. Fexuprazan safeguards the esophagus from hydrochloric acid-induced damage by suppressing NLRP1/Caspase-1/GSDMD pyroptotic pathway - Frontiers, accessed August 29, 2025, https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1410904/full
14. Fexuprazan hydrochloride - Drug Targets, Indications, Patents - Patsnap Synapse, accessed August 29, 2025, https://synapse.patsnap.com/drug/8cf85eea83d446fe9678b316003fded4
15. FEXUPRAZAN HCl - FDA Verification Portal, accessed August 29, 2025, https://verification.fda.gov.ph/files/DR-XY48448_PI_01.pdf
16. Development of Physiologically Based Pharmacokinetic Model for Orally Administered Fexuprazan in Humans - PMC, accessed August 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8229463/
17. (PDF) Development of Physiologically Based Pharmacokinetic ..., accessed August 29, 2025, https://www.researchgate.net/publication/351997815_Development_of_Physiologically_Based_Pharmacokinetic_Model_for_Orally_Administered_Fexuprazan_in_Humans
18. Randomized Multicenter Study to Evaluate the Efficacy and Safety of Fexuprazan According to the Timing of Dosing in Patients With Erosive Esophagitis - Journal of Neurogastroenterology and Motility, accessed August 29, 2025, https://www.jnmjournal.org/journal/view.html?uid=1948&vmd=Full
19. Daewoong Pharmaceutical Presents New Clinical Data of Fexuprazan at Digestive Disease Week 2023 - PR Newswire, accessed August 29, 2025, https://www.prnewswire.com/news-releases/daewoong-pharmaceutical-presents-new-clinical-data-of-fexuprazan-at-digestive-disease-week-2023-301829434.html
20. Pharmacokinetic interactions between fexuprazan, a potassium‐competitive acid blocker, and nonsteroidal anti‐inflammatory drugs in healthy males - PMC, accessed August 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11067709/
21. Preference for On-Demand Fexuprazan Therapy in Gastroesophageal Reflux Disease: A Prospective Cohort Study - MDPI, accessed August 29, 2025, https://www.mdpi.com/2075-4426/15/1/19
22. The efficacy and safety of fexuprazan in treating erosive esophagitis: a phase III, randomized, double-blind, multicenter study. - FirstWord Pharma, accessed August 29, 2025, https://firstwordpharma.com/story/5820903
23. A PHASE 3, NON-INFERIORITY RANDOMIZED CONTROLLED TRIAL WITH... - Moon S - - May 7 2023 - DDW ePosters, accessed August 29, 2025, https://eposters.ddw.org/ddw/2023/ddw-2023/379464/sukyong.moon.a.phase.3.non-inferiority.randomized.controlled.trial.with.html?f=listing%3D3%2Abrowseby%3D8%2Asortby%3D2%2Amedia%3D3%2Alabel%3D26102
24. (PDF) A Phase III Head-to-Head Study to Compare the Efficacy and ..., accessed August 29, 2025, https://www.researchgate.net/publication/381061376_A_Phase_III_Head-to-Head_Study_to_Compare_the_Efficacy_and_Safety_of_Fexuprazan_and_Esomeprazole_in_Treating_Patients_with_Erosive_Esophagitis
25. Phase III clinical data of Fexuprazan shows efficacy in gastroesophageal reflux disease.- Daewoong Pharma - Medthority, accessed August 29, 2025, https://www.medthority.com/news/2020/05/phase-iii-clinical-data-of-fexuprazan-shows-efficacy-in-gastroesophageal-reflux-disease.--daewoong-pharma
26. Efficacy and Safety of Fexuprazan in Patients with Acute or Chronic Gastritis - PMC, accessed August 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10651377/
27. Efficacy and Safety of Fexuprazan in Patients with Acute or Chronic Gastritis, accessed August 29, 2025, https://snu.elsevierpure.com/en/publications/efficacy-and-safety-of-fexuprazan-in-patients-with-acute-or-chron
28. Sun Pharma Laboratories Gets CDSCO Panel Nod To Manufacture, Market Fexuprazan Hydrochloride Tablets - Medical Dialogues, accessed August 29, 2025, https://medicaldialogues.in/news/industry/pharma/sun-pharma-laboratories-gets-cdsco-panel-nod-to-manufacture-market-fexuprazan-hydrochloride-tablets-140940
29. Efficacy of Fexuprazan for Prevention or Control of Gastritis Symptoms in Patients on Treatment With Systemic Steroids | ClinicalTrials.gov, accessed August 29, 2025, https://clinicaltrials.gov/study/NCT05946135
30. (PDF) Comparing Proton Pump Inhibitors and Emerging Acid-Suppressive Therapies in Gastroesophageal Reflux Disease: A Systematic Review - ResearchGate, accessed August 29, 2025, https://www.researchgate.net/publication/391860528_Comparing_Proton_Pump_Inhibitors_and_Emerging_Acid-Suppressive_Therapies_in_Gastroesophageal_Reflux_Disease_A_Systematic_Review
31. Daewoong wins approval for GERD treatment Fexuclu in Chile - KED Global, accessed August 29, 2025, https://www.kedglobal.com/bio-pharma/newsView/ked202303140013
32. Daewoong's GERD drug Fexuclue is about to expand to 24 countries in 18 months - KBR, accessed August 29, 2025, https://www.koreabiomed.com/news/articleView.html?idxno=23371
33. Daewoong Pharmaceutical's Fexuclue Wins Marketing Authorization in Chile, accessed August 29, 2025, https://www.businesskorea.co.kr/news/articleView.html?idxno=110950
34. Daewoong Pharmaceutical Seeks Approval for Fexuprazan in China's Anti-Ulcer Drug Market - BioPharma APAC, accessed August 29, 2025, https://biopharmaapac.com/news/83/3447/-daewoong-pharmaceutical-seeks-approval-for-fexuprazan-in-chinas-anti-ulcer-drug-market.html
35. Daewoong Pharmaceutical submits a new drug application for Fexuprazan in China challenging the world's largest market for anti-ulcer drugs - PR Newswire, accessed August 29, 2025, https://www.prnewswire.com/apac/news-releases/daewoong-pharmaceutical-submits-a-new-drug-application-for-fexuprazan-in-china-challenging-the-worlds-largest-market-for-anti-ulcer-drugs-301888318.html
36. Daewoong submits NDA in China for anti-ulcer drug Fexuprazan, accessed August 29, 2025, https://www.pharmaceutical-technology.com/news/daewoong-china-fexuprazan/
37. Daewoong Pharmaceutical Regaining Rights to Fexuprazan in the United States and Canada upon Termination of License Agreement with Neurogastrx - PR Newswire, accessed August 29, 2025, https://www.prnewswire.com/news-releases/daewoong-pharmaceutical-regaining-rights-to-fexuprazan-in-the-united-states-and-canada-upon-termination-of-license-agreement-with-neurogastrx-301841938.html
38. Daewoong Pharmaceutical Announces 2023 Financial Results - FirstWord Pharma, accessed August 29, 2025, https://firstwordpharma.com/story/5825367
39. Daewoong, Chong Kun Dang to co-market GERD drug Fexuclue < Pharma < Article - KBR, accessed August 29, 2025, https://www.koreabiomed.com/news/articleView.html?idxno=23718
40. Sun Pharma launches Fexuprazan tablets 40 mg in India | Capital Market News, accessed August 29, 2025, https://www.business-standard.com/markets/capital-market-news/sun-pharma-launches-fexuprazan-tablets-40-mg-in-india-125040700221_1.html
41. Daewoong Pharmaceutical's Fexuprazan takes its first step into Africa Entering into a partnership with Cooper Pharma, the No. 1 pharmaceutical company in Morocco in the field of digestive health - PR Newswire, accessed August 29, 2025, https://www.prnewswire.com/apac/news-releases/daewoong-pharmaceuticals-fexuprazan-takes-its-first-step-into-africa-entering-into-a-partnership-with-cooper-pharma-the-no-1-pharmaceutical-company-in-morocco-in-the-field-of-digestive-health-301883697.html